



News Release

November 4, 2016
Maruho Co., Ltd.

Maruho Launches Acne Vulgaris Treatment “Epiduo[®] Gel” in Japan

Osaka (Japan), November 4, 2016 – Maruho Co., Ltd. (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces today that it has launched acne vulgaris treatment Epiduo[®] Gel “Epiduo” in Japan. In July 2016, Galderma KK (Head Office: Tokyo, Japan, President and CEO: Leslaw Rudy) received manufacturing and marketing approval in Japan for Epiduo.

Epiduo is a topical formulation of a fixed-dose drug combination containing adapalene and benzoyl peroxide developed by Galderma Pharma S.A. (“Galderma SA”, Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman). Since its first marketing authorization in Europe in 2007, Epiduo has now been approved in 60 countries around the world. (As of October 2016) Maruho and Galderma SA agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs, including Epiduo, for dermatology in Japan. Maruho will market, provide medical information and collect medical information about Epiduo in Japan.

While providing a new treatment option for acne vulgaris, Maruho hopes that with the promotion of medical information it can contribute to the health of patients suffering from skin diseases in Japan.

Product Profile: Epiduo[®] Gel

Formulation/Dose	Gel formulation containing 1mg adapalene (0.1%) and 25mg benzoyl peroxide (2.5%).
Indication	Acne vulgaris
Dosage and Administration	Apply an appropriate amount to the affected area once a day, after washing the face.
Packaging	Tube: 15g × 10
NHI Drug Price Standard	1g 159.60yen
Date of Approval	July 4, 2016
Date of NHI Price Listing	August 31, 2016
Date of Launch	November 4, 2016
Manufacturer	Galderma KK

About Acne

Excess sebum production as a result of hormone levels etc. can cause pores to become clogged and the inflammation of hair follicles and sebaceous glands resulting in a skin disease commonly known as acne or pimples. When hair follicles are clogged with sebum, P.acnes in the follicle can grow causing a red inflammation with pus.

Maruho's initiatives towards treatment for Acne

Maruho markets oral and topical agents for acne.

Maruho also runs an information website to provide information to patients suffering from acne.

www.maruho.co.jp/kanja/nikibi (As Maruho only markets these treatments for customers in Japan, the information is only provided in Japanese).

About Galderma

Dating back to 1981, Galderma is now present in 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

For more information, please visit www.galderma.com

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,335 employees (as of the end of September 2015), and net sales were approximately 67.0 billion yen in its 2015 fiscal year. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit www.maruho.co.jp/english

Contact Information:

Maruho Co., Ltd.

Corporate Communications Dept.

Roger Matthews

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6376-8679

Email: kouhou@mii.maruho.co.jp